Thieler Law Corp advises investors with losses exceeding $100,000 of the December 21, 2015 lead plaintiff deadline in a class action lawsuit filed against Valeant Pharmaceuticals International Inc (NYSE:VRX) (“Valeant Pharmaceuticals International Inc” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Valeant Pharmaceuticals International Inc securities between February 23, 2015 and October 20, 2015, have until December 21, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Valeant Pharmaceuticals International Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Valeant Pharmaceuticals International Inc was buying drugs and considerably raising prices, and was subpoenaed by U.S. prosecutors looking for information on its pricing decisions, drug distribution and patient assistance programs.

On October 21, 2015, Citron Research issued a report that Valeant Pharmaceuticals International Inc and Philidor formed an entire network of phantom captive pharmacies to create fake sales of drugs or to avoid inspection from auditors. Shares of Valeant Pharmaceuticals International Inc (NYSE:VRX) declined to as low as $$28.13 per share on October 21, 2015.

On October 26, 2015, Valeant Pharmaceuticals International Inc stated that it was assigning a committee to review Valeant Pharmaceuticals International Inc relationship with Philidor and will continue with plans to focus on developing new drugs rather than obtaining older ones and raising their prices. Following this news, Valeant Pharmaceuticals International Inc shares fell by as much as $9.56, or more than 8%, during intra-day trading on October 26, 2015.

If you were negatively impacted by your investment in Valeant Pharmaceuticals International Inc securities between February 23, 2015 and October 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185